Noida-based Redcliffe Labs has announced the strategic divestment of its fertility services business, Crysta IVF, to DElhi-based Moon Care, the healthcare arm of MMG Group. The transaction reflects Redcliffe Labs' continued focus on strengthening its diagnostics capabilities and expanding its presence in preventive and advanced diagnostic services across India.
The move allows the organisation to consolidate further its efforts to deliver technology-led accessible, accurate, and affordable diagnostic solutions at scale.
At the same time, Crysta IVF, which achieved EBITDA profitability at the start of FY26, is well-positioned to continue its growth journey under the dedicated leadership of Moon Care, which will further strengthen its focus on delivering specialized fertility care and expanding access to reproductive health services.
Speaking on the development, Aditya Kandoi, Founder & CEO, Redcliffe Labs, said: “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare - with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further."
For patients already served by Crysta IVF, the transition will be seamless, with no change to ongoing operations. The existing Crysta IVF team and leadership will continue to lead the business, working closely with Moon Care, which will provide strategic guidance and mentorship. This ensures continuity of care without disruption, while also enabling the introduction of new initiatives to further enhance patient outcomes.
For Redcliffe Labs, the deal signifies a sharpened focus on the diagnostic segment. This will enable the company to accelerate expansion, increase testing volumes, and deepen its presence in preventive healthcare, driving greater impact through early detection and accessible care.
